Format

Send to

Choose Destination
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S21-S22. doi: 10.1016/j.ijmyco.2016.09.044. Epub 2016 Nov 14.

Host-directed therapies for multidrug resistant tuberculosis.

Author information

1
Division of Infection and Immunity, University College London, NIHR Biomedical Research Center, UCL Hospitals NHS, Foundation Trust, London, UK. Electronic address: a.zumla@ucl.ac.uk.
2
Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Abstract

Tuberculosis (TB) causes 1.3 million deaths annually. There are 0.5 million cases of multidrug resistant TB (MDR-TB) and the number of cases is rising globally. The current status quo of the lengthy treatment duration and poor treatment outcomes associated with MDR/extensively drug-resistant TB, and those with comorbidity of TB with human immunodeficiency virus and noncommunicable diseases in sub-Saharan Africa is unacceptable. The TB drug pipeline remains sparse. New innovations for shortening the duration of therapy and improving treatment outcomes (cure and long-term functional disability due to lung damage) are urgently required. A wide range of host-directed therapies (HDT) are now available which require evaluation as adjuncts to current TB drug treatment. Examples are: The Host-directed Therapies Network consortium of 64 partners was launched in Cape Town after a meeting hosted by the South African Medical Research Council in April 2015. This network (which is open to anyone interested) plans to take forward a wide range of HDTs in randomized, placebo-controlled clinical trials as adjuncts to current TB treatment regimens with the aims of.

KEYWORDS:

Host-directed therapy; MDR-TB; Tuberculosis

PMID:
28043559
DOI:
10.1016/j.ijmyco.2016.09.044
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center